Skip to main content

Table 2 Intensity of pain – change during double-blind treatment (mean ± SD, or ratio of means and 95% CI)

From: Effectiveness of Menthacarin on symptoms of irritable bowel syndromeWirksamkeit von Menthacarin bei Symptomen des Reizdarmsyndroms

  Total dataset Patients with IBS
Trial Aa Menthacarin −2.47 ± 1.31
(n = 19)
−2.42 ± 1.24
(n = 12)
Placebo −1.35 ± 1.66
(n = 20)
−1.22 ± 1.72
(n = 9)
Ratio of means 1.83 [1.08, 3.83] 1.98 [0.92, 12.00]
Trial Bb Menthacarin −3.59 ± 2.11
(n = 108)
−3.51 ± 2.01
(n = 40)
Enteric-soluble formulation −3.30 ± 2.04
(n = 105)
−3.52 ± 1.80
(n = 42)
Ratio of means 1.09 [0.93, 1.29] 1.00 [0.78, 1.27]
Trial Cb Menthacarin −4.57 ± 2.80
(n = 60)
−3.62 ± 3.40
(n = 5)
Cisapride −4.59 ± 2.48
(n = 58)
−3.97 ± 2.75
(n = 3)
Ratio of means 1.00 [0.80, 1.23] 0.91 [–∞, +∞]
  1. Menthacarin® is the active ingredient of the product Carmenthin® (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany)
  2. SD standard deviation, CI confidence interval, IBS irritable bowel syndrome
  3. aScale: 0 … 5
  4. bScale: 0 … 10